Abstract
We have previously reported that β3-adrenoceptor agonists dilate retinal blood vessels, but their effects on retinal neurons have been unclear. In this study, we examined the action of the β3-adrenoceptor agonist CL316243 against retinal damage induced by intravitreal injection of N-methyl-D-aspartate (NMDA) in rats. CL316243 was injected into the vitreous cavity before, with, or after intravitreal NMDA injection. Seven days after NMDA injection, cell loss in the ganglion cell layer (GCL) and thinning of the inner plexiform layer were observed. The reduction in the number of cells in the GCL was diminished by injection of CL316243 at 15, 30, 60, or 120 min after NMDA injection, whereas no significant protective effect was observed when CL316243 was administered 240 min after NMDA injection. Neither preinjection of CL316243 30 min before NMDA nor simultaneous injection of CL316243 with NMDA exerted any protective effect. The β3-adrenoceptor antagonist L748337 almost completely abolished the protection conferred by CL316243 injection 120 min after NMDA injection. The number of parvalbumin-positive amacrine cells was decreased in eyes examined 1 day after NMDA treatment, but this was prevented by CL316243 injection at 120 min after NMDA injection. These results suggest that CL316243 exerts protective effects against NMDA-induced damage by stimulation of β3-adrenoceptors. β3-adrenoceptor agonists may be effective candidates for the treatment of retinal diseases associated with glutamate-induced excitotoxicity, including glaucoma and diabetic retinopathy.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Al-Gayyar MM, Abdelsaid MA, Matragoon S, Pillai BA, El-Remessy AB (2010) Neurovascular protective effect of FeTPPs in N-methyl-D-aspartate model: similarities to diabetes. Am J Pathol 177:1187–1197
Ambati J, Chalam KV, Chawla DK, D'Angio CT, Guillet EG, Rose SJ, Vanderlinde RE, Ambati BK (1997) Elevated gamma-aminobutyric acid, glutamate, and vascular endothelial growth factor levels in the vitreous of patients with proliferative diabetic retinopathy. Arch Ophthalmol 115:1161–1166
Barber AJ, Lieth E, Khin SA, Antonetti DA, Buchanan AG, Gardner TW (1998) Neural apoptosis in the retina during experimental and human diabetes. Early onset and effect of insulin. J Clin Invest 102:783–791
De La Cruz JP, Gonzalez-Correa JA, Guerrero A, de la Cuesta FS (2004) Pharmacological approach to diabetic retinopathy. Diabetes Metab Res Rev 20:91–113
Dkhissi O, Chanut E, Wasowicz M, Savoldelli M, Nguyen-Legros J, Minvielle F, Versaux-Botteri C (1999) Retinal TUNEL-positive cells and high glutamate levels in vitreous humor of mutant quail with a glaucoma-like disorder. Invest Ophthalmol Vis Sci 40:990–995
Dreyer EB, Zurakowski D, Schumer RA, Podos SM, Lipton SA (1996) Elevated glutamate levels in the vitreous body of humans and monkeys with glaucoma. Arch Ophthalmol 114:299–305
Flammer J, Orgul S, Costa VP, Orzalesi N, Krieglstein GK, Serra LM, Renard JP, Stefansson E (2002) The impact of ocular blood flow in glaucoma. Prog Retin Eye Res 21:359–393
Grieshaber MC, Flammer J (2005) Blood flow in glaucoma. Curr Opin Ophthalmol 16:79–83
Hallett PJ, Standaert DG (2004) Rationale for and use of NMDA receptor antagonists in Parkinson's disease. Pharmacol Ther 102:155–174
Horio N, Clermont AC, Abiko A, Abiko T, Shoelson BD, Bursell SE, Feener EP (2004) Angiotensin AT1 receptor antagonism normalizes retinal blood flow and acetylcholine-induced vasodilatation in normotensive diabetic rats. Diabetologia 47:113–123
Hynd MR, Scott HL, Dodd PR (2004) Glutamate-mediated excitotoxicity and neurodegeneration in Alzheimer's disease. Neurochem Int 45:583–595
Izumi Y, Hammerman SB, Kirby CO, Benz AM, Olney JW, Zorumski CF (2003) Involvement of glutamate in ischemic neurodegeneration in isolated retina. Vis Neurosci 20:97–107
Kim SA, Jeon JH, Son MJ, Cha J, Chun MH, Kim IB (2010) Changes in transcript and protein levels of calbindin D28k, calretinin and parvalbumin, and numbers of neuronal populations expressing these proteins in an ischemia model of rat retina. Anat Cell Biol 43:218–229
Lam TT, Abler AS, Kwong JM, Tso MO (1999) N-methyl-D-aspartate (NMDA)-induced apoptosis in rat retina. Invest Ophthalmol Vis Sci 40:2391–2397
Mori A, Saigo O, Hanada M, Nakahara T, Ishii K (2009a) Hyperglycemia accelerates impairment of vasodilator responses to acetylcholine of retinal blood vessels in rats. J Pharmacol Sci 110:160–168
Mori A, Ishii T, Kuroki T, Shigeta N, Sakamoto K, Nakahara T, Ishii K (2009b) The prostanoid EP2 receptor agonist ONO-AE1-259-01 protects against glutamate-induced neurotoxicity in rat retina. Eur J Pharmacol 616:64–67
Mori A, Miwa T, Sakamoto K, Nakahara T, Ishii K (2010) Pharmacological evidence for the presence of functional β3-adrenoceptors in rat retinal blood vessels. Naunyn- Schmiedeberg’s Arch Pharmacol 382:119–126
Nakazawa T, Kaneko Y, Mori A, Saito M, Sakamoto K, Nakahara T, Ishii K (2007) Attenuation of nitric oxide- and prostaglandin-independent vasodilation of retinal arterioles induced by acetylcholine in streptozotocin-treated rats. Vascular Pharmacol 46:153–159
Nakazawa T, Sato A, Mori A, Saito M, Sakamoto K, Nakahara T, Ishii K (2008) β-Adrenoceptor-mediated vasodilation of retinal blood vessels is reduced in streptozotocin-induced diabetic rats. Vascular Pharmacol 49:77–83
Ng YK, Zeng XX, Ling EA (2004) Expression of glutamate receptors and calcium-binding proteins in the retina of streptozotocin-induced diabetic rats. Brain Res 1018:66–72
Nucci C, Tartaglione R, Rombolà L, Morrone LA, Fazzi E, Bagetta G (2005) Neurochemical evidence to implicate elevated glutamate in the mechanisms of high intraocular pressure (IOP)-induced retinal ganglion cell death in rat. Neurotoxicology 26:935–941
Pulido JE, Pulido JS, Erie JC, Arroyo J, Bertram K, Lu MJ, Shippy SA (2007) A role for excitatory amino acids in diabetic eye disease. Exp Diabetes Res 2007:36150
Schmetterer L, Wolzt M (1999) Ocular blood flow and associated functional deviations in diabetic retinopathy. Diabetologia 42:387–405
Siliprandi R, Canella R, Carmignoto G, Schiavo N, Zanellato A, Zanoni R, Vantini G (1992) N-methyl-D-aspartate-induced neurotoxicity in the adult rat retina. Vis Neurosci 8:567–573
Ueda K, Nakahara T, Hoshino M, Mori A, Sakamoto K, Ishii K (2010) Retinal blood vessels are damaged in a rat model of NMDA-induced retinal degeneration. Neurosci Lett 485:55–59
Vrydag W, Michel MC (2007) Tools to study β3-adrenoceptors. Naunyn-Schmiedeberg’s Arch Pharmacol 374:385–398
Wässle H, Grünert U, Röhrenbeck J (1993) Immunocytochemical staining of AII-amacrine cells in the rat retina with antibodies against parvalbumin. J Comp Neurol 332:407–420
Zheng L, Gong B, Hatala DA, Kern TS (2007) Retinal ischemia and reperfusion causes capillary degeneration: similarities to diabetes. Invest Ophthalmol Vis Sci 48:361–367
Acknowledgments
The authors thank Ryosuke Okada and Ikumi Hayashi for technical assistance. This study was supported by a Grant-in-Aid for Scientific Research on Innovative Areas (no. 23122517, T.N.) and a Grant-in-Aid for Scientific Research (C) from the Ministry of Education, Culture, Sports, Science and Technology of Japan (no. 23590112, T.N.).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Oikawa, F., Nakahara, T., Akanuma, K. et al. Protective effects of the β3-adrenoceptor agonist CL316243 against N-methyl-D-aspartate-induced retinal neurotoxicity. Naunyn-Schmiedeberg's Arch Pharmacol 385, 1077–1081 (2012). https://doi.org/10.1007/s00210-012-0796-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00210-012-0796-1